Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Posted on 17 Nov 2026
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers evaluate amyloid processing without relying on cerebrospinal fluid samples, while anti-amyloid treatment studies also require methods to assess biological responses and potential links with amyloid-related imaging abnormalities. A new plasma assay now enables quantification of multiple amyloid beta variants from a single blood sample.
C2N Diagnostics has launched C2N-Aβ-MAA (6x), a plasma multi-analyte assay for amyloid beta (Aβ) proteins. The assay uses high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) to precisely quantify six Aβ peptide variants from a single plasma sample: Aβ37, Aβ38, Aβ39, Aβ40, Aβ42, and Aβ43.

According to C2N, measuring all six variants from a single sample may improve efficiency and provide additional value in clinical research. The company expects the assay to support biopharmaceutical clinical trials investigating amyloid biology in Alzheimer’s disease and related neurodegenerative conditions. The test is available for research use only and complements C2N’s existing Aβ-MAA (6x) assay for cerebrospinal fluid.
By measuring both shorter and longer Aβ peptides, the assay is intended to help researchers evaluate how treatments affect amyloid processing. C2N said these measurements may support assessments of pharmacodynamic responses and dose selection in clinical trials, including studies of investigational therapies such as γ-secretase modulators. The assay may also support exploratory research into relationships between Aβ peptide profiles and amyloid-related imaging abnormalities associated with amyloid-targeting treatments.
C2N said its biomarkers have contributed to more than 200 clinical studies worldwide. More than 90,000 Precivity-related biomarker measurements have been reported in peer-reviewed publications, with additional manuscripts under review. The company’s clinical Precivity blood test portfolio includes PrecivityAD, PrecivityAD2, and Precivity-ApoE.
“Our introduction of the C2N-Aβ-MAA (6x) assay in blood underscores C2N’s commitment to innovation for clinical researchers by advancing novel treatment trials and providing improved diagnostic tools. This next-generation assay uses a single sample preparation to elicit important new insights into neurological conditions and treatments impacting brain amyloid processing,” said Dr. Joel Braunstein, CEO and President of C2N.







.jpg)